In regulated medical device organisations, collaboration is not simply people working together. It is the coordinated execution of quality activities where every decision, approval, and hand-off must be attributable, time-stamped, and retrievable on demand. ISO 13485 requires that quality records demonstrate who did what and when. FDA QMSR and EU MDR extend that obligation to corrective actions, design changes, and supplier controls. When those activities span multiple functions and locations, the stakes for structured collaboration are high.
Informal tools introduce risk that is rarely obvious until an audit. Email threads fragment decisions across inboxes. Shared drives lack access controls and version discipline. Messaging apps leave no durable, attributable record. Auditors frequently cite these gaps under records management and corrective action clauses, because the organisation cannot demonstrate that the right person reviewed a document, agreed to a decision, or received a task at a specific point in time.
Regulated collaboration requires more than good intentions. It requires documented decisions tied to quality records, controlled access aligned with role and training status, and audit trails that survive personnel changes and system migrations. For distributed teams across time zones, this adds a coordination layer: quality events cannot wait for a morning standup, and CAPA hand-offs cannot rely on a colleague being online to receive a message.
Multi-person quality workflows, from nonconformance review to change control sign-off, depend on structured hand-offs with defined owners, deadlines, and escalation paths. Without that structure, tasks stall, records go unsigned, and closure timelines extend. The problem is not that teams lack commitment. It is that the process architecture does not enforce the accountability that regulators expect.
The whitepaper below shows how qmsWrapper structures multi-person quality workflows to keep collaboration auditable across functions, sites, and time zones.
